Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2026 18:04 ET | Source: Robbins LLP

Robbins LLP Reminds SLP Stockholders of its Investigation into Simulation Plus, Inc.; Contact the Firm for Information

Robbins LLP Reminds SLP Stockholders of its Investigation into Simulation Plus, Inc.; Contact the Firm for Information
June 05, 2026 13:57 ET | Source: Robbins LLP

Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited

Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate
June 03, 2026 16:50 ET | Source: Robbins LLP

Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws

Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
June 02, 2026 19:18 ET | Source: Robbins LLP

SLP Shareholder Alert: Robbins LLP Reminds Simulation Plus, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SLP Shareholder Alert: Robbins LLP Reminds Simulation Plus, Inc. Stockholders that it is Investigating the Company's Officers and Directors
May 14, 2026 17:37 ET | Source: Robbins LLP

IMMP Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Immutep Limited Class Action Lawsuit

Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate
April 21, 2026 14:34 ET | Source: Robbins LLP

Robbins LLP Urges ATRA Stockholders to Contact the Firm for Information About the Class Action Against Atara Biotherapeutics, Inc.

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
April 20, 2026 16:30 ET | Source: Robbins LLP

GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Gossamer Bio, Inc. (GOSS) Misled Investors Regarding the Viability of its PROSERA Study
April 20, 2026 16:29 ET | Source: Robbins LLP

IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that ImuunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate
April 20, 2026 16:05 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
April 10, 2026 14:06 ET | Source: Robbins LLP

Robbins LLP Reminds CORT Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action

Robbins LLP is Investigating Allegations that Corcept Therapeutics Incorporated (CORT) Misled Investors Regarding the Viability of its New Product Candidat